home / stock / nspr / nspr quote
Last: | $5.4297 |
---|---|
Change Percent: | 0.18% |
Open: | $5.49 |
Close: | $5.4297 |
High: | $5.55 |
Low: | $5.32 |
Volume: | 132,772 |
Last Trade Date Time: | 06/08/2021 12:54:35 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.4297 | $5.49 | $5.4297 | $5.55 | $5.32 | 132,772 | 06-08-2021 |
$5.35 | $5.41 | $5.35 | $5.6 | $5.27 | 164,184 | 05-31-2021 |
$5.4 | $5.12 | $5.4 | $5.5 | $5.12 | 131,432 | 05-21-2021 |
$5.1 | $5.05 | $5.1 | $5.215 | $4.98 | 140,814 | 05-20-2021 |
$5.04 | $4.95 | $5.04 | $5.149 | $4.84 | 155,642 | 05-19-2021 |
$5.26 | $4.71 | $5.26 | $5.29 | $4.65 | 540,914 | 05-18-2021 |
$4.59 | $4.65 | $4.59 | $4.74 | $4.46 | 169,021 | 05-17-2021 |
$4.59 | $4.47 | $4.59 | $4.7499 | $4.47 | 162,643 | 05-14-2021 |
$4.42 | $4.83 | $4.42 | $5.07 | $4.3318 | 363,137 | 05-13-2021 |
$4.77 | $4.93 | $4.77 | $5 | $4.73 | 305,892 | 05-12-2021 |
$4.95 | $4.31 | $4.95 | $5.004 | $4.31 | 418,005 | 05-11-2021 |
$4.74 | $5.04 | $4.74 | $5.05 | $4.6 | 587,193 | 05-10-2021 |
$5.04 | $4.85 | $5.04 | $5.8099 | $4.85 | 1,179,449 | 05-07-2021 |
$4.88 | $5.34 | $4.88 | $5.45 | $4.7697 | 445,334 | 05-06-2021 |
$5.44 | $5.2 | $5.44 | $5.5 | $5.07 | 864,162 | 05-05-2021 |
$5.18 | $5.31 | $5.18 | $5.31 | $5 | 342,811 | 05-04-2021 |
$5.3 | $5.99 | $5.3 | $6 | $5.3 | 489,444 | 05-03-2021 |
$6.02 | $6 | $6.02 | $6.17 | $5.9 | 270,163 | 04-30-2021 |
$6.11 | $6.54 | $6.11 | $6.5899 | $6.06 | 450,749 | 04-29-2021 |
$6.51 | $6.86 | $6.51 | $7.16 | $6.35 | 858,013 | 04-28-2021 |
News, Short Squeeze, Breakout and More Instantly...
TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Marvin Slosman, Chief Executive Officer, will deliver a company update presentati...
TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract of the one-year outcomes from its C-GUARDIANS IDE clinical trial of t...